Zobrazeno 1 - 10
of 189
pro vyhledávání: '"tumor infiltrating lymphocytes (TIL)"'
Autor:
Milena Kalaitsidou, Owen R. Moon, Martina Sykorova, Leyuan Bao, Yun Qu, Sujita Sukumaran, Michael Valentine, Xingliang Zhou, Veethika Pandey, Kay Foos, Sergey Medvedev, Daniel J. Powell Jr, Akshata Udyavar, Eric Gschweng, Ruben Rodriguez, Mark E. Dudley, Robert E. Hawkins, Gray Kueberuwa, John S. Bridgeman
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Transfer of autologous tumor infiltrating lymphocytes (TIL) to patients with refractory melanoma has shown clinical efficacy in a number of trials. However, extending the clinical benefit to patients with other cancers poses a challenge. Inefficient
Externí odkaz:
https://doaj.org/article/7f1e15ebf5834e83a34fa2733d953fd0
Autor:
Sarah Bazargan, Brittany Bunch, Awino Maureiq E. Ojwang‘, Jamie Blauvelt, Annick Landin, Johannes Ali, Dominique Abrahams, Cheryl Cox, Amy M. Hall, Matthew S. Beatty, Michael Poch, Katarzyna A. Rejniak, Shari Pilon-Thomas
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundNew therapeutics in development for bladder cancer need to address the recalcitrant nature of the disease. Intravesical adoptive cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) can potentially induce durable responses in bladde
Externí odkaz:
https://doaj.org/article/6a8fb4e5eb7f4745af9760012bdd39fc
Autor:
Elena Tassi, Alice Bergamini, Jessica Wignall, Miriam Sant’Angelo, Emanuela Brunetto, Chiara Balestrieri, Miriam Redegalli, Alessia Potenza, Danilo Abbati, Francesco Manfredi, Maria Giulia Cangi, Gilda Magliacane, Fabiola Scalisi, Eliana Ruggiero, Maria Chiara Maffia, Federica Trippitelli, Emanuela Rabaiotti, Raffaella Cioffi, Luca Bocciolone, Giorgio Candotti, Massimo Candiani, Gianluca Taccagni, Birgit Schultes, Claudio Doglioni, Giorgia Mangili, Chiara Bonini
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionDespite predicted efficacy, immunotherapy in epithelial ovarian cancer (EOC) has limited clinical benefit and the prognosis of patients remains poor. There is thus a strong need for better identifying local immune dynamics and immune-supp
Externí odkaz:
https://doaj.org/article/922dcb22f26e463191e455023be98e2a
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
A major challenge in developing an effective adoptive cancer immunotherapy is the ex-vivo generation of tumor-reactive cells in sufficient numbers and with enhanced cytotoxic potential. It was recently demonstrated that culturing of activated murine
Externí odkaz:
https://doaj.org/article/96cb62cf91db4e359ddc8317e97d3904
Autor:
Dong Liu, Lara Rosaline Heij, Zoltan Czigany, Edgar Dahl, Sven Arke Lang, Tom Florian Ulmer, Tom Luedde, Ulf Peter Neumann, Jan Bednarsch
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-18 (2022)
Abstract Cholangiocarcinoma (CCA) is the second most common primary liver cancer and associated with a dismal prognosis due to the lack of an efficient systemic therapy. In contrast to other cancers, new immunotherapies have demonstrated unsatisfacto
Externí odkaz:
https://doaj.org/article/ec66657d903d40aea7cb9620a8d5976b
Publikováno v:
Pathology and Oncology Research, Vol 28 (2022)
Background: PBRM1 gene abnormalities were recently found to play a role in tumor development and tumor immune activity. This article will explore the clinicopathological and molecular changes and tumor immune activity of the abnormal SWI/SNF complex
Externí odkaz:
https://doaj.org/article/ece1ded147f543abb90e736cf505912e
Autor:
Weili Jia, Tianchen Zhang, Qianyun Yao, Jianhui Li, Ye Nie, Xinjun Lei, Zhenzhen Mao, Yanfang Wang, Wen Shi, Wenjie Song
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells found in the tumor microenvironment. TLS can influence primary hepatic carcinoma (PHC) occurrence and have an active role in cancer. TLS can promote or inhibit the growth of
Externí odkaz:
https://doaj.org/article/5b00992db739426aa881536baa02d652
Autor:
Qin Tan, Chaoting Zhang, Wenjun Yang, Ying Liu, Palashati Heyilimu, Dongdong Feng, Liying Xing, Yang Ke, Zheming Lu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantigens derived from somat
Externí odkaz:
https://doaj.org/article/8af61dc477154b638ed4589968b3ff9b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.